|
Hemorrhoids
|
0.010 |
Biomarker
|
disease |
BEFREE |
The number of haemorrhoid specimens showing positive immunoreactivity of NOS in the vascular endothelium was significantly higher than that in rectal tissue for NOS1 (11/14 (79%) vs 1/6 (17%); p=0.018) and NOS3 (8/14 (57%) vs 0/6 (0%); p=0.042), but not for NOS2 (6/14 (43%) vs 4/6 (67%); p=0.63).
|
30058493 |
2020 |
|
Absence of sensation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We have used iontophoresis in vivo to study the effect of the NOS inhibitor L-NAME (L-NG-Nitroarginine methyl ester) and the NO donors SIN-1 (3-Morpholinosydnonimine hydrochloride) and SNOG (S-Nitrosoglutathione) on VCN units under urethane anaesthesia.
|
31494975 |
2020 |
|
Aspirin exacerbated respiratory disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Prevalence of allergy was significantly higher in AFRS (100%), CCAD (97.6%), CRSwNP/CC (84.6%), and AERD (82.6%) when compared with CRSwNP NOS (56.1%) (p < 0.001).
|
31600866 |
2020 |
|
Primary Myelofibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The total nitrite/nitrate (NOx) level was augmented in the plasma of PMF patients (p<0.001), while nitrotyrosine and iNOS were generally increased in the granulocytes of MPN patients.
|
30570876 |
2019 |
|
Anxiety Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
BD-II and BD-NOS more frequently had an AD at psychiatric onset, with panic disorder being the most common AD.
|
31733039 |
2019 |
|
Cerebral Palsy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The 14 repeat-long allele of the CCTTTn NOS2A microsatellite was present in 27% of CP patients vs 12.3% of controls, showing an odds ratio (OR) = 2.6531 and 95% confidence interval (CI) = 0.9612-7.3232 (P < 0.0469).
|
29931509 |
2019 |
|
Fatty Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Dietary nitrate fuels a nitrate-nitrite-NO signaling pathway, which prevented many features of metabolic syndrome and liver steatosis that developed in mice fed a high-fat diet, with or without combination with an inhibitor of NOS (l-NAME).
|
30559212 |
2019 |
|
Leukoplakia, Oral
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Quantitative polymerase chain reactions (qPCRs) were utilized to detect the NOS2 levels in fresh-frozen tissue samples of NOM (n = 6), OL (n = 20), and OSCC (n = 15).
|
31379002 |
2019 |
|
Myopathy
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In conclusion, these data depict that insulin resistance through CYP2E1 may contribute to the pathogenesis of myopathic changes including myocardial contractile dysfunction, oxidative stress and mitochondrial injury, possibly through activation of iNOS and NLRP3 signaling.
|
30463689 |
2019 |
|
Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The relation of miR-19a expression to OS was further recognized by fixed model within the studies of sample size less than 150 (HRs = 1.68, CI: 1.35-2.08), NOS scores greater than or equal to 8 (HRs = 1.53, CI: 1.13-2.06) or less than 8 (HRs = 1.89, CI: 1.58-2.27), specimen derived from tumor (HRs = 1.73, CI: 1.42-2.12) or blood (HRs = 1.87, CI: 1.46-2.40) and the patients of osteosarcoma (HRs = 7.17, CI: 5.04-10.21).
|
31015372 |
2019 |
|
Panic Disorder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
BD-II and BD-NOS more frequently had an AD at psychiatric onset, with panic disorder being the most common AD.
|
31733039 |
2019 |
|
Reticuloendotheliosis, X-linked
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, JFNE and fraction D significantly decreased the mRNA expression of iNOS, v-rel reticuloendotheliosis viral oncogene homolog A (RELA), and nuclear factor of <i>κ</i> light polypeptide gene enhancer in B cells 1 (NF-<i>κ</i>B1), whereas an increase in the mRNA expression of conserved helix-loop-helix ubiquitous kinase (CHUK) was observed.
|
31068381 |
2019 |
|
CREST Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Endothelial form of NOS activation would be suppressed, and the process of neuronal migration and outgrowth would be activated to participant in the pathological mechanism of lcSSc.
|
30980594 |
2019 |
|
Elastosis perforans serpiginosa
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, expression of inducible NO synthase (iNOS) and IκB‑α degradation were enhanced in PH‑EPS‑treated cells.
|
31638207 |
2019 |
|
Perinatal anoxic-ischemic brain injury
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We investigated whether the risk for cerebral palsy (CP) increases when an expansion of the - 2.5 kb (CCTTT)n microsatellite in the NOS2A gene and a single nucleotide polymorphism (SNP) in -C511T of the IL- IL-1β gene promoter occur in patients after perinatal hypoxic-ischemic encephalopathy.
|
29931509 |
2019 |
|
Osteosarcoma of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
The relation of miR-19a expression to OS was further recognized by fixed model within the studies of sample size less than 150 (HRs = 1.68, CI: 1.35-2.08), NOS scores greater than or equal to 8 (HRs = 1.53, CI: 1.13-2.06) or less than 8 (HRs = 1.89, CI: 1.58-2.27), specimen derived from tumor (HRs = 1.73, CI: 1.42-2.12) or blood (HRs = 1.87, CI: 1.46-2.40) and the patients of osteosarcoma (HRs = 7.17, CI: 5.04-10.21).
|
31015372 |
2019 |
|
Traditional Serrated Adenoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A total of 22 mucosal lesions were revealed in 8 CRC patients comprising conventional IBD-associated dysplasia (4 lesions), PPLs as serrated change/dysplasia NOS (11 lesions), villous hypermucinous change (5 lesions), and two true serrated lesions (one sessile serrated adenoma and one traditional serrated adenoma).
|
30679085 |
2019 |
|
Mediastinal (Thymic) Large B-Cell Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
PD-L1 positive rates were all higher in PMBCL and DHL than in DLBCL-NOS by SP263, SP142, RNAscope, and FISH (P = 0.001, P < 0.001, P = 0.005 and P < 0.001, respectively).
|
31150165 |
2019 |
|
Liver regeneration disorder
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Nitric oxide (NO) derived from the catalytic activity of Nos2 plays a beneficial role in liver regeneration (LR) after partial hepatectomy (PH).
|
28670514 |
2019 |
|
Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using data from the National Cancer Data Base, 2010-2015, we examined characteristics and outcomes of T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL, <i>N</i> = 622) relative to unspecified diffuse large B-cell lymphoma (DLBCL-NOS, <i>N</i> = 91,588) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL, <i>N</i> = 2240).
|
31287335 |
2019 |
|
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using data from the National Cancer Data Base, 2010-2015, we examined characteristics and outcomes of T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL, <i>N</i> = 622) relative to unspecified diffuse large B-cell lymphoma (DLBCL-NOS, <i>N</i> = 91,588) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL, <i>N</i> = 2240).
|
31287335 |
2019 |
|
Childhood Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The relation of miR-19a expression to OS was further recognized by fixed model within the studies of sample size less than 150 (HRs = 1.68, CI: 1.35-2.08), NOS scores greater than or equal to 8 (HRs = 1.53, CI: 1.13-2.06) or less than 8 (HRs = 1.89, CI: 1.58-2.27), specimen derived from tumor (HRs = 1.73, CI: 1.42-2.12) or blood (HRs = 1.87, CI: 1.46-2.40) and the patients of osteosarcoma (HRs = 7.17, CI: 5.04-10.21).
|
31015372 |
2019 |
|
Central Nervous System Embryonal Neoplasm
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Three patients (2 with high-grade glioma, 1 with CNS embryonal tumor NOS) showed a partial response to treatment at the primary tumor site and 2 of 3 had progression of metastatic disease.
|
30681550 |
2019 |
|
Nodular Lymphocyte Predominant Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using data from the National Cancer Data Base, 2010-2015, we examined characteristics and outcomes of T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL, <i>N</i> = 622) relative to unspecified diffuse large B-cell lymphoma (DLBCL-NOS, <i>N</i> = 91,588) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL, <i>N</i> = 2240).
|
31287335 |
2019 |
|
Refractory Follicular Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Exploratory genomic analysis showed two cases of PTCL-NOS with sustained response had a common mutation in LRRK2 and high prevalence of FOXO1 mutation in relapsed/refractory follicular lymphoma.
|
30520026 |
2019 |